Company

Corimmun is a clinical drug-developing company which focuses on inflammatory mechanisms in heart failure and atherosclerosis.

The company receives constant scientific support from the outstanding university groups of its founders. Corimmun has developed several potent drugs, which can be brought to market approval after testing in larger patient studies.